Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting

Signaling Pathways

Items 21-30 of 55

Page
per page
  1. KRN 633
    A5760 KRN 633
    Summary: VEGFR inhibitor,ATP-competitive
      insoluble in EtOH; insoluble in H2O; ≥13.75 mg/mL
  2. RAF265
    A8313 RAF265
    Target: Raf|VEGFR
    Summary: Multiple intracellular kinases inhibitor
      ≥25.9 mg/mL
  3. Pazopanib Hydrochloride
    A8347 Pazopanib Hydrochloride
    Summary: VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor
      ≥11.1 mg/mL
  4. Axitinib (AG 013736)
    A8370 Axitinib (AG 013736)
     1 Citation
    Target: VEGFR|PDGFR|c-Kit
    Summary: VEGFR1/ c-Kit inhibitor
      insoluble in H2O; ≥19.3 mg/mL
  5. Dovitinib Dilactic acid
    A8418 Dovitinib Dilactic acid
    Summary: FLT3 inhibitor
      ≥57.3 mg/mL
  6. Telatinib (BAY 57-9352)
    A8550 Telatinib (BAY 57-9352)
    Target: VEGFR|PDGFR|c-Kit
    Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor
      insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL
  7. Vandetanib (ZD6474)
    A8555 Vandetanib (ZD6474)
    Target: VEGFR|EGFR
    Summary: VEGFR2/EGFR antagonist
      insoluble in H2O; ≥11.88 mg/mL
  8. SKLB1002
    B1305 SKLB1002
    Summary: VEGFR2 inhibitor,potent and ATP-competitve
  9. CP-673451
    B2173 CP-673451
    Target: PDGFR
    Summary: PDGFRα/β inhibitor,potent and selective
  10. Apatinib
    B2303 Apatinib
     1 Citation
    Summary: VEGFR2 inhibitor, orally bioavailable, selective
      ≥49.4 mg/mL

Items 21-30 of 55

Page
per page